— December-quarter revenues increased 5% annually to $2.22 billion, vs. $2.2 billion expected
— Revenue of Bausch + Lomb/International, the main business segment, grew 3% annually; Salix segment revenue was up 21%
— Received FDA approval for ARAZLO Lotion for the topical treatment of acne vulgaris in young adults
ADVERTISEMENT
— Raised capital allocation for research and development by 14% in fiscal 2019, compared to last year
— Expects full-year 2020 revenues to be in the range of $8.65 billion to $8.85 billion
— Looking for adjusted EBITDA in the range of $3.50 billion to $3.65 billion for fiscal 2020